Publication date: Aug 05, 2024
The single-stranded RNA genome of SARS-CoV-2 encodes several structural and non-structural proteins, among which the papain-like protease (PLpro) is crucial for viral replication and immune evasion and has emerged as a promising therapeutic target. The current study aims to discover new inhibitors of PLpro that can simultaneously disrupt its protease and deubiquitinase activities. Using multiple computational approaches, six compounds (CP1-CP6) were selected from our in-house compounds database, with higher docking scores (-7. 97 kcal/mol to -8. 14 kcal/mol) and fitted well in the active pocket of PLpro. Furthermore, utilizing microscale molecular dynamics simulations (MD), the dynamic behavior of selected compounds was studied. Those molecules strongly binds at the PLpro active site and forms stable complexes. The dynamic motions suggest that the binding of CP1-CP6 brought the protein to a closed conformational state, thereby altering its normal function. In an in vitro evaluation, CP2 showed the most significant inhibitory potential for PLpro (protease activity = 2. 71 +/- 0. 33 μM and deubiquitinase activity = 3. 11 +/- 0. 75 μM), followed by CP1, CP5, CP4 and CP6. Additionally, CP1-CP6 showed no cytotoxicity at a concentration of 30 μM in the human BJ cell line.
Concepts | Keywords |
---|---|
30m | Deubiquitinase assay |
Cytotoxicity | Molecular dynamic simulation |
Genome | Papain-like protease |
Viral | Protease assay |
SARS-CoV-2 |
Semantics
Type | Source | Name |
---|---|---|
drug | DRUGBANK | Papain |
pathway | KEGG | Viral replication |
disease | IDO | site |
disease | IDO | cell |
disease | IDO | assay |